Evidence and Renovascular Disease: Trials and Mistrials?

Stephen C. Textor; Sandra M. Herrmann

doi:10.1053/j.ajkd.2017.04.013

Evidence and Renovascular Disease: Trials and Mistrials?

Stephen C. Textor, Sandra M. Herrmann

Nephrology and Hypertension

Research output: Contribution to journal › Editorial › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	160-163
Number of pages	4
Journal	American Journal of Kidney Diseases
Volume	70
Issue number	2
DOIs	https://doi.org/10.1053/j.ajkd.2017.04.013
State	Published - Aug 2017

ASJC Scopus subject areas

Nephrology

Access to Document

10.1053/j.ajkd.2017.04.013

Cite this

@article{21339bc7645f4a86bd23eac236ef28a9,

title = "Evidence and Renovascular Disease: Trials and Mistrials?",

author = "Textor, {Stephen C.} and Herrmann, {Sandra M.}",

note = "Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute for Diabetes, Digestive and Kidney Diseases (NIDDK) or the National Institutes of Health (NIH). Support: This work was supported by grant R01 DK100081 from the NIDDK and NIH/National Center for Research Resources , Clinical and Translational Science Awards grant UL1 RR024150 . Financial Disclosures: Dr Textor participates as a section editor for UpToDate and on the Data Safety Monitoring Board for Sentien Therapeutics. Dr Herrmann declares that she has no relevant financial interests. Peer Review: Evaluated by an Associate Editor and Deputy Editor Berns. ",

year = "2017",

month = aug,

doi = "10.1053/j.ajkd.2017.04.013",

language = "English (US)",

volume = "70",

pages = "160--163",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Evidence and Renovascular Disease

T2 - Trials and Mistrials?

AU - Textor, Stephen C.

AU - Herrmann, Sandra M.

N1 - Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute for Diabetes, Digestive and Kidney Diseases (NIDDK) or the National Institutes of Health (NIH). Support: This work was supported by grant R01 DK100081 from the NIDDK and NIH/National Center for Research Resources , Clinical and Translational Science Awards grant UL1 RR024150 . Financial Disclosures: Dr Textor participates as a section editor for UpToDate and on the Data Safety Monitoring Board for Sentien Therapeutics. Dr Herrmann declares that she has no relevant financial interests. Peer Review: Evaluated by an Associate Editor and Deputy Editor Berns.

PY - 2017/8

Y1 - 2017/8

UR - http://www.scopus.com/inward/record.url?scp=85019854460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019854460&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2017.04.013

DO - 10.1053/j.ajkd.2017.04.013

M3 - Editorial

C2 - 28535904

AN - SCOPUS:85019854460

SN - 0272-6386

VL - 70

SP - 160

EP - 163

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 2

ER -

Evidence and Renovascular Disease: Trials and Mistrials?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this